



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE BECOMES A GENEGO CENTER OF EXCELLENCE

St. Joseph, Michigan, July 15th, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, today announced that the University of Miami Miller School of Medicine has become a certified GeneGo Center of Excellence (COE). Miller School of Medicine researchers will have access to GeneGo’s MetaCore, training and advanced support. COE will provide a pathway analysis environment and support for all the school’s researchers. They will also act as a training facility for GeneGo in the University of Miami.

"We are looking forward to working with GeneGo as the company provides the kind of forward-looking bioinformatics software that we are excited to use," said Sawsan Khuri, Ph.D., assistant research professor at the Center for Computational Science at the University of Miami Miller School of Medicine. "The technology will be extremely useful for researchers here, especially those at the Miami Project to Cure Paralysis and the Miami Institute for Human Genomics, both of which will benefit greatly from the collaboration with GeneGo as we work toward new scientific breakthroughs."

"The University of Miami has some important thought leaders in this field and we are pleased to be working with them" said Julie Bryant, Vice President of Business Development at GeneGo. "The school of medicine works with one million patients annually and it is encouraging that we can help them to improve their quality of life."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 4.7™, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.7™ is designed for prediction of human metabolism, toxicity and biological effects for novel

small molecules compounds. MetaBase™ represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com

MetaCore™, MetaBase™, MetaDrug™, MetaLink™, MetaDiscovery™, MetaTox™, MetaMiner™ and 1-2-3 Workflow™ are trademarks of GeneGo, Inc.